RITUXAN HYCELA® (Rituximab and Hyaluronidase human)

July 7, 2017April 5, 2020 RR FDA Approvals

The FDA on June 22, 2017 granted regular approval to RITUXAN HYCELA® for adult patients with Follicular lymphoma, Diffuse Large B-Cell Lymphoma, and Chronic Lymphocytic Leukemia. RITUXAN HYCELA® is a product of Genentech Inc.

Post navigation

RITUXAN HYCELA® (Rituximab and Hyaluronidase human)

TAFINLAR® and MEKINIST® (Dabrafenib and Trametinib) The FDA on June 22, 2017 granted regular approvals to TAFINLAR® and MEKINIST® administered in combination for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. TAFINLAR® and MEKINIST® are products of Novartis Pharmaceuticals Inc. These are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC.

Bottom Ad

Subscribe

Search for:

Ad 1

Ad 2

Ad 3

Ad 4

PRIVACY
TERMS
DISCLAIMER
CONTACT

Top Ad

Related Posts:

Bottom Ad

Subscribe